TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06150443

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT)
Description: Two osteopathic primary care physicians will performing osteopathic manipulative techniques with a minimum of three direct techniques focused on carpal tunnel. These techniques will include the interosseous membrane technique, the flexor retinaculum soft tissue technique, and the radiocarpal somatic dysfunction technique. They will also evaluate and treat the cervical spine, with particular attention to the C5-7 levels, all the way to the wrist and hand as they see fit based on the findings of their osteopathic structural exam.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic manipulative treatment (OMT)
Description: Two osteopathic primary care physicians will performing osteopathic manipulative techniques with a minimum of three direct techniques focused on carpal tunnel. These techniques will include the interosseous membrane technique, the flexor retinaculum soft tissue technique, and the radiocarpal somatic dysfunction technique. They will also evaluate and treat the cervical spine, with particular attention to the C5-7 levels, all the way to the wrist and hand as they see fit based on the findings of their osteopathic structural exam.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment
Description: Conservative therapy will be defined as including the use of splints, NSAIDs, opioids, and therapeutic injection of the carpal tunnel with steroids. Physical therapy will be excluded from the conservative therapy regimen.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment
Description: Conservative therapy will be defined as including the use of splints, NSAIDs, opioids, and therapeutic injection of the carpal tunnel with steroids. Physical therapy will be excluded from the conservative therapy regimen.
Study: NCT06244927

Intervention type: PROCEDURE
Intervention: Replantation surgery
Description: Surgery
Study: NCT05498298

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biopotentials measurement with gtec device
Description: A measurement of 40 minutes is performed with the gtec g.Hlamp to collect biopotential signals. 32 electrodes are attached to the body (abdomen, thorax and back).
Study: NCT05124938

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory investigations for control: a-Complete blood count. b-Liver function test. c-kidney function test. d-thyroid-stimulating hormone,T3 and T4. e-Assessment of levels of CA19-9.
Description: a-Complete blood count. b-Liver function test. c-kidney function test d-thyroid-stimulating hormone,T3 and T4. e-Assessment of levels of CA19-9.

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory investigations for control: a-Complete blood count. b-Liver function test. c-kidney function test. d-thyroid-stimulating hormone,T3 and T4. e-Assessment of levels of CA19-9.
Description: a-Complete blood count. b-Liver function test. c-kidney function test d-thyroid-stimulating hormone,T3 and T4. e-Assessment of levels of CA19-9.

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory investigations for control: a-Complete blood count. b-Liver function test. c-kidney function test. d-thyroid-stimulating hormone,T3 and T4. e-Assessment of levels of CA19-9.
Description: a-Complete blood count. b-Liver function test. c-kidney function test d-thyroid-stimulating hormone,T3 and T4. e-Assessment of levels of CA19-9.
Study: NCT05557812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: non-eugenol based ZOE base material with Ferric Sulfate in primary molar pulpotomies
Description: non-eugenol based ZOE base material placed over ferric sulphate, during vital pulp therapy (pulpotomy) in primary molars

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eugenol based zinc oxide and Ferric Sulfate
Description: eugenol based zinc oxide base material placed over Ferric Sulfate medicament, during vital pulp therapy (pulpotomy) in primary molars
Study: NCT06570824

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active TMS
Description: Transcranial magnetic stimulation using MagVenture XP Orange Stimulator using active side of MagVenture Cool-B70 coil

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active TMS
Description: Transcranial magnetic stimulation using MagVenture XP Orange Stimulator using active side of MagVenture Cool-B70 coil

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham TMS
Description: Sham transcranial magnetic stimulation using MagVenture XP Orange Stimulator, flipping the active side of the MagVenture Cool-B70 coil

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham TMS
Description: Sham transcranial magnetic stimulation using MagVenture XP Orange Stimulator, flipping the active side of the MagVenture Cool-B70 coil
Study: NCT06297603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retatrutide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retatrutide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retatrutide
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT04854798

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Splenic Ultrasound
Description: Daily ultrasound application to the spleen of approximately 18 minutes for up to 7 days, in addition to standard clinical care
Study: NCT06318156

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Infrared thermal imaging
Description: A well-trained physician donned the Finger TPS tactile pressure measurement system (Finger TPS II, BTLETG03, USA), methodically applying a consistent 60N force with a single thumb vertically downward on the acupoints of the L1 to L5 spinal segments, in accordance with the human cutaneous nerve segment map. Additionally, environmental conditions were meticulously controlled-temperature maintained between 20°C to 25°C, relative humidity at 50% to 60%, with gentle indoor lighting, quiet, and stable airflow. The MESH T-1000 Smart medical infrared thermograph, produced by Wuhan Gewu Optoelectronics Technology Co., Ltd., was utilized to assess the surface temperature of the patient's pressure-sensitive acupoint areas.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Infrared thermal imaging
Description: A well-trained physician donned the Finger TPS tactile pressure measurement system (Finger TPS II, BTLETG03, USA), methodically applying a consistent 60N force with a single thumb vertically downward on the acupoints of the L1 to L5 spinal segments, in accordance with the human cutaneous nerve segment map. Additionally, environmental conditions were meticulously controlled-temperature maintained between 20°C to 25°C, relative humidity at 50% to 60%, with gentle indoor lighting, quiet, and stable airflow. The MESH T-1000 Smart medical infrared thermograph, produced by Wuhan Gewu Optoelectronics Technology Co., Ltd., was utilized to assess the surface temperature of the patient's pressure-sensitive acupoint areas.
Study: NCT05270135

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ASAP
Description: ASAP is an intervention geared toward increasing non-stigmatized syringe sales to people who inject drugs to prevent bloodborne illnesses.
Study: NCT05728541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYH2043
Description: Patients will receive SYH2043 once everyday on day 1-21 of each 28-day cycle
Study: NCT00115960

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV-1 gag DNA
Description: DNA vaccine containing the HIV gene gag

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV-1 gag DNA
Description: DNA vaccine containing the HIV gene gag

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV-1 gag DNA
Description: DNA vaccine containing the HIV gene gag

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV-1 gag DNA
Description: DNA vaccine containing the HIV gene gag

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV-1 gag DNA
Description: DNA vaccine containing the HIV gene gag

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV-1 gag DNA
Description: DNA vaccine containing the HIV gene gag

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-15 DNA adjuvant
Description: Cytokine injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-15 DNA adjuvant
Description: Cytokine injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-15 DNA adjuvant
Description: Cytokine injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-15 DNA adjuvant
Description: Cytokine injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-15 DNA adjuvant
Description: Cytokine injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-12 DNA adjuvant
Description: Cytokine injection
Study: NCT05672030

Intervention type: OTHER
Intervention: Non-Interventional
Description: No intervention.

Intervention type: OTHER
Intervention: Non-Interventional
Description: No intervention.

Intervention type: OTHER
Intervention: Non-Interventional
Description: No intervention.
Study: NCT05587153

Intervention type: OTHER
Intervention: perfusion index in all parturient recruited for the study
Description: Using perfusion index and positional hemodynamic changes for the prediction of postspinal hypotension in all parturient recruited for the study
Study: NCT05000801

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC vaccine
Description: Autologous/or HLA-matched donors' DCs loaded with WT1/TERT/survivin
Study: NCT05412329

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC012F injection
Description: GC012F injection is a autologous dual CAR-T targeted BCMA and CD19. A single infusion of CART cells will be administered intravenously.
Study: NCT06447792

Intervention type: OTHER
Intervention: Loading protocol
Description: The prosthetic restoration and functional loading of the dental implant.

Intervention type: OTHER
Intervention: Loading protocol
Description: The prosthetic restoration and functional loading of the dental implant.

Intervention type: OTHER
Intervention: Loading protocol
Description: The prosthetic restoration and functional loading of the dental implant.
Study: NCT04723030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carleilizumab+apathy mesylate+radiotherapy+paclitaxel (albumin-bound)
Description: Carrilizumab ：200mg,q2w; Apatinib :250mg,d1; which is taken continuously for 5 days and stopped for 2 days, and stopped for 2 weeks after radiotherapy.~Taxol :125mg/m2,q2w; Gemcitabine :1000mg/m2, q2w; cisplatin :25mg/m2, q2w; Radiotherapy:30Gy, divided into five times and completed within one week.
Study: NCT05182112

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole liver irradiation (WLI)
Description: Whole liver irradiation (WLI) to a total dose 1800cGy in 10 fractions will be given over 2 weeks with simultaneously integrated boost (SIB) to deliver focal doses of 3600cGy (dose level 1) and 4800cGy (dose level 2) to select gross lesions. SIBl dose assignment will be according to the dose escalation scheme, with all patients in dose level 1 receiving boost of 3600cGy to select lesions and those in dose level 2 receiving boosts of 4800cGy to select lesions. At least one lesion will be selected for dose escalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Cisplatin
Description: Patients will start cisplatin 10 mg/m2 and gemcitabine 600 mg/m2 intravenously q2 weeks for 1 cycle while undergoing simulation and radiation treatment planning procedures. After completion of CRT, adjuvant cisplatin 25 mg/m2 and gemcitabine 600 mg/m2 q2 weeks will be continued until progression or unacceptable toxicity.
Study: NCT05970172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Oral
Study: NCT05122819

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mandibular Molar Extraction Under Local Anesthesia
Description: Local Anaesthetic to be used: 2% Lidocaine in 1.8 ml cartridge (regularly used for dental anaesthesia regardless of the technique).~Pain on injection and local anaesthesia success will be checked by using numeric pain rating scale (NPRS).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mandibular Molar Extraction Under Local Anesthesia
Description: Local Anaesthetic to be used: 2% Lidocaine in 1.8 ml cartridge (regularly used for dental anaesthesia regardless of the technique).~Pain on injection and local anaesthesia success will be checked by using numeric pain rating scale (NPRS).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mandibular Molar Extraction Under Local Anesthesia
Description: Local Anaesthetic to be used: 2% Lidocaine in 1.8 ml cartridge (regularly used for dental anaesthesia regardless of the technique).~Pain on injection and local anaesthesia success will be checked by using numeric pain rating scale (NPRS).
Study: NCT05587790

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Management Intervention
Description: Participants attend virtual dietary education sessions and over time create a diet plan that satisfies their individual needs. Participants aim to lose 1-2 pounds weekly until a BMI of 25 is reached. Participants are evaluated through daily self-weighing, dietary records, and anthropometric measures of waist and hip circumference, and body composition.
Study: NCT05514392

Intervention type: DEVICE
Intervention: HP Cosmos Torqoalizer
Description: Participants will sign a consent form approved by the ethics committee. Height, weight, thigh length, leg length, foot length and kinematic foot length will be recorded before data collection. Ergometer positions will be adjusted according to participant preference. Participants will be invited to the Health Sciences University Physiotherapy and Rehabilitation Hall once. Before starting the exercise of the participants, muscle activity, balance assessment, leg fatigue will be evaluated. Participants will be made an exercise protocol. At the end of the exercise, necessary evaluations will be made again, and then the person will rest for 1 hour. After 1 hour, the exercise groups will change; Persons receiving single foot bicycle ergometer training will receive double foot bicycle ergometer training, and the group receiving double foot bicycle ergometer training will receive single foot bicycle ergometer training. Necessary evaluations will be repeated at the end of the training.

Intervention type: DEVICE
Intervention: HP Cosmos Torqoalizer
Description: Participants will sign a consent form approved by the ethics committee. Height, weight, thigh length, leg length, foot length and kinematic foot length will be recorded before data collection. Ergometer positions will be adjusted according to participant preference. Participants will be invited to the Health Sciences University Physiotherapy and Rehabilitation Hall once. Before starting the exercise of the participants, muscle activity, balance assessment, leg fatigue will be evaluated. Participants will be made an exercise protocol. At the end of the exercise, necessary evaluations will be made again, and then the person will rest for 1 hour. After 1 hour, the exercise groups will change; Persons receiving single foot bicycle ergometer training will receive double foot bicycle ergometer training, and the group receiving double foot bicycle ergometer training will receive single foot bicycle ergometer training. Necessary evaluations will be repeated at the end of the training.
Study: NCT04625153

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RC18 160mg
Description: RC18 160mg is injected subcutaneously once a week for 48 times.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RC18 240mg
Description: RC18 240mg is injected subcutaneously once a week for 48 times.
Study: NCT06011226

Intervention type: OTHER
Intervention: focus groups
Description: A dozen patients with Chiari malformation and syringomyelia (n = 4) or isolated Chiari malformation (n = 4) or isolated syringomyelia (n = 4) will be brought together in at least two focus groups. Each focus group will include 5 to 8 patients and will last approximately 1 to 2 hours. The focus groups will be recorded (audio only, no personal data will be collected during these sessions) and will be conducted in the presence of a neurosurgeon and a psychologist, who will moderate the session.

Intervention type: OTHER
Intervention: questionnaire
Description: developed questionnaire will be proposed to the patients in phase 2 and 3

Intervention type: OTHER
Intervention: questionnaire
Description: developed questionnaire will be proposed to the patients in phase 2 and 3
Study: NCT05751408

Intervention type: PROCEDURE
Intervention: gait analysis using 3D (Vicon) and IMU (Movella)
Description: Subjects are measured using Vicon 3D analysis, combined with IMU-sensors

Intervention type: PROCEDURE
Intervention: gait analysis using 3D (Vicon) and IMU (Movella)
Description: Subjects are measured using Vicon 3D analysis, combined with IMU-sensors
Study: NCT05999435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAU-7b for 3 cycles
Description: Three cycles of 14 days of once-a-day intake of LAU-7b, each followed by a treatment intake pause of14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAU-7b for 1 cycle, then placebo
Description: One cycle of 14 days of once-a-day intake of LAU-7b followed by two cycles of 14 days of placebo administered similarly, each followed by a treatment intake pause of14 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for 3 cycles
Description: Three cycles of 14 days of once-a-day intake of placebo, each followed by a treatment intake pause of14 days
Study: NCT06647160

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue star MAX-5 spectacle lens
Description: The children in the experimental group will wear Blue star MAX-5 spectacle lens and receive follow-up examinations every half year.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single-vision spectacle lens
Description: The children in the single-vision lenses group will wear single-vision spectacle lens and receive follow-up examinations every half year.
Study: NCT05211947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: BI 425809
Study: NCT05408169

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Suggested deadline for return of screening test
Description: A screening invitation letter modified to state, highlighted in yellow: Please return your kit within \[X\] weeks (by \[DD.MM.YYYY\]) or as soon as possible.
Study: NCT05805501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobemstomig
Description: Participants will receive IV tobemstomig Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobemstomig
Description: Participants will receive IV tobemstomig Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Participants will receive IV tiragolumab Q3W.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Participants will receive IV pembrolizumab Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Participants will receive axitinib PO BID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Participants will receive axitinib PO BID.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Axitinib
Description: Participants will receive axitinib PO BID.
Study: NCT05523895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Description: Pimavanserin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Description: Pimavanserin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pimavanserin matching placebo
Study: NCT06034743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baxdrostat
Description: Baxdrostat tablet administered orally, once daily (QD). Unit dose strengths:~* 1 mg per tablet for 1 mg baxdrostat Arm;~* 2 mg per tablet for 2 mg baxdrostat Arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baxdrostat
Description: Baxdrostat tablet administered orally, once daily (QD). Unit dose strengths:~* 1 mg per tablet for 1 mg baxdrostat Arm;~* 2 mg per tablet for 2 mg baxdrostat Arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet matching baxdrostat, administered orally, once daily (QD).
Study: NCT05976581

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic alert
Description: An alert will appear in the electronic health record that provides options for diagnostic testing based on low, medium, or high probability of bacterial pneumonia.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Electronic alert
Description: An alert will appear in the electronic health record that provides options for diagnostic testing based on low, medium, or high probability of bacterial pneumonia.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured communication of test results
Description: A clinical research team member will send an electronic message to the primary care team on behalf of the antimicrobial stewardship program with structured guidance to stop or de-escalate antibiotics and document these recommendations in the patient's chart.
Study: NCT05348317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VetReach
Description: Telehealth-delivered MI-CBT substance use disorder care model
Study: NCT05440786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Orally